Germany · Delayed Price · Currency is EUR Viking Therapeutics Company Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
The company was incorporated in 2012 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2012 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 36 |
| CEO | Brian Lian |
Contact Details
Address: 9920 Pacific Heights Boulevard San Diego, Delaware 92121 United States | |
| Phone | 858 704 4660 |
| Website | vikingtherapeutics.com |
Stock Details
| Ticker Symbol | 1VT |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Brian Lian | Chief Executive Officer |
| Gregory Zante | Chief Financial Officer |
| Marianne Mancini | Chief Operating Officer |